

# INVESTOR RELATIONS

## MetrioPharm Investor Relations News QII 2024

### 18th Annual General Meeting of MetrioPharm AG

The 18th Annual General Meeting took place on June 27, 2024 in Zurich. With the annual report, management and the Board of Directors of MetrioPharm AG provided an overview of the company's activities in the 2023 fiscal year.

These included the EU-funded iMPact project, in which MetrioPharm's lead compound MP1032 was clinically tested in COVID-19. The project was successfully completed and thus fully funded by the grant. It resulted in a publication of the data in a renowned scientific journal: The Lancet Regional Health Europe.

MetrioPharm AG began conducting preclinical studies in the indication Duchenne muscular dystrophy in 2022. MetrioPharm was supported by co-funding from the patient organization Duchenne UK. Based on these results, the US Food and Drug Administration (FDA) decided to grant Orphan Drug Designation in May 2023 and Rare Pediatric Disease Status in October. MetrioPharm is currently conducting further preclinical models in this indication, with results expected in the second half of 2024. They will serve as the basis for clinical testing of the lead compound MP1032 in Duchenne muscular dystrophy.

The MetrioPharm team is supported in the preparation of this clinical trial by numerous scientific and clinical advisors, several of whom are members of MetrioPharm's Scientific Advisory Board.

Management and the Board of Directors also provided information on the progress of the current funding round: In 2023, there were two successful closings totaling CHF 18.4 million. The financing round will continue in 2024/25.

Following the approval of the annual report and the annual financial statements for 2023 and the discharge of the Board of Directors, Mr. Jörg Gruber and Mr. Ekkehard Brysch were confirmed as a member of the Board of Directors for a further three years. Mr. Rudolf Stäger was also confirmed as a member of the Board of Directors for a further three years.

Of the total share capital of CHF 41,981,655.00, divided into 209,908,275 registered shares with a nominal value of CHF 0.20, 145,885,398 shares were represented. This equates to 69.5% of the shares issued.

## MetrioPharm AG Company Calendar 2024

06-07 January, Longwood Healthcare Leaders Conference, San Francisco, USA

09 January, Annual Wuxi Global Forum 2024, San Francisco, USA

08-10 January, Biotech Showcase, San Francisco, USA

10 January, FreeMind's Annual Non-Dilutive Funding Summit, San Francisco, USA

26-27 February, BIO CEO & Investor Conference, New York, USA

29 February, Annual European Life Sciences CEO Forum, Zurich, Switzerland

01-02 March, Duchenne UK 2024 New Horizons Conference, London, UK

03-06 March, Muscular Dystrophy Association (MDA) Conference, Orlando, USA

18-20 March, Bio-Europe Spring, Barcelona, Spain

22-23 April, Swiss Biotech Day, Basel, Switzerland

24-25 April, Asia Bio Partnering Forum, Singapore

29-30 April, LSX World Congress, Biotech, Healthtech, Medtech, London, UK

12-14 May, BioEquity Europe, San Sebastian, Spain

03-06 June, BIO International Convention, San Diego, USA

27-30 June, Parents Project Muscular Dystrophy (PPMD), Orlando, USA

10-11 September, ChinaBio Partnering Forum 2024, Shanghai, China

25-26 September, 24th Annual Biotech in Europe Forum, Basel, Switzerland

08-12 October, World Muscle Society Annual Congress, Prague, Czech Republic

29-31 October, 15th World Congress on Targeting Mitochondria, Berlin, Germany

04-06 November, BIO-Europe Conference, Stockholm, Sweden

## MetrioPharm AG informs

MetrioPharm uses various channels to inform its shareholders:

- In addition to the quarterly newsletter, we also keep you informed about current events in the company with press releases. The press releases can also be found [on our website here](#). If you have not yet been added to our distribution list for press releases, please send us an e-mail at [invest@metriopharm.com](mailto:invest@metriopharm.com) and we will add you to the distribution list as soon as possible.

- You can also network with MetrioPharm via LinkedIn. We use [our LinkedIn profile](#) to inform shareholders, experts and business partners about the latest company developments. Please feel free to include us in your LinkedIn community by invitation.

**Your contacts:****MetrioPharm**

Investor Relations

T +41 44 552 7190

E [invest@metriopharm.com](mailto:invest@metriopharm.com)W [www.metriopharm.com](http://www.metriopharm.com)**akampion**

Dr. Ludger Wess / Ines-Regina Buth

Managing Partners

[info@akampion.com](mailto:info@akampion.com)

Tel. +49 40 88 16 59 64 /

Tel. +49 30 23 63 27 68